Objectives: Mycobacterium avium subspecies paratuberculosis (MAP) has been targeted for treatment with clarithromycin and rifamycin derivatives in numerous cases of Crohn's disease (CD). 6-Mercaptopurine and its pro-drug azathioprine are widely used as immunomodulators in the treatment of CD and have recently been shown to have anti-MAP activity in vitro. The objectives of the study were to evaluate the in vitro effects on MAP of (i) 6-mercaptopurine when combined with each of eight conventional antibacterial agents with in vitro anti-MAP activity and (ii) antibacterial combinations consisting of two drugs (clarithromycin combined with amikacin, rifampicin, ciprofloxacin or ethambutol) and three drugs (clarithromycin, rifabutin and clofazimine).
Introduction
Treatment of mycobacterial diseases requires a combination of drugs to limit antimicrobial drug resistance during long-term therapy and to deal with the innate susceptibility differences among mycobacteria in different physiological states, e.g. dormant in vivo. 1 In vitro interaction studies on antimicrobial agents are necessary to select synergistic and avoid antagonistic antimicrobial combinations.
Mycobacterium avium subspecies paratuberculosis (MAP) is the causative agent of Johne's disease, a chronic inflammatory bowel disease affecting a broad range of animals including primates. 2 It is also the most investigated potential causative agent of Crohn's disease (CD), a chronic, debilitating inflammatory bowel disease of humans. 3, 4 Owing to the strong MAP-CD association, 5, 6 potential anti-MAP agents (macrolides, rifamycin derivatives and clofazimine) were used in clinical trials and case studies with promising outcomes in most reports, 7 -12 but not in all. 13, 14 Earlier in vitro studies have shown that macrolides, especially clarithromycin, are highly effective against MAP. 15, 16 This observation is consistent with antimicrobial susceptibility data for M. avium complex (MAC). 17, 18 Presently, the recommended treatment and prophylactic regimens for disease due to MAC are combinations of two or three drugs: a macrolide (clarithromycin or azithromycin) in combination with rifampicin or rifabutin and/or ethambutol. 19 For CD, a combination of antimicrobials along with immunosuppressive agent(s) was recommended as preferable to using antibiotics alone. 20 Azathioprine is an immunomodulator that induces and maintains remission in CD. 21 Azathioprine and its derivative 6-mercaptopurine are eventually metabolized in vivo forming thioguanine nucleotides (TGNs), which induce cytotoxicity and immunosuppression. 22 Interestingly, 6-mercaptopurine was recently shown to have anti-MAP activity in vitro. 23, 24 The objectives of this work were to evaluate the actions of clarithromycin or 6-mercaptopurine with other anti-MAP agents and with each other on the in vitro growth of MAP.
Materials and methods

MAP strains
Nine human (CD cases) isolates of MAP were tested. They included five clinical strains (UCF3, UCF4, UCF5, UCF7 and UCF8) kindly donated by Saleh Naser (University of Central Florida, Orlando, FL, USA) and four ATCC strains (43015, 43544, 43545 and 49164). All the isolates were verified as MAP by assay for insertion sequence (IS)900 by PCR, 25 as well as by in vitro growth characteristics. The isolates were grown in Middlebrook 7H9 broth (Becton Dickinson, Sparks, MD, USA) supplemented with 10% oleic acid/albumin/dextrose/catalase (OADC) and 2 mg/L mycobactin J (Allied Monitor, Fayette, MO, USA). Eight-week-old cultures were harvested and resuspended in fresh medium containing glycerol (final concentration of 20%, v/v). The bacterial suspension was declumped by vortexing in screw-capped glass test tubes containing 3 mm glass beads. The suspension was then allowed to stand for 30 min. The supernatant of MAP obtained by this method was found to contain bacilli evenly spread out as single cells on a Ziehl -Neelsen-stained smear. The harvested supernatant was stored as aliquots at 2808C.
Preparation of inocula for in vitro drug susceptibility testing
Frozen stock cultures were thawed and added to 4 mL of PBS in screw-capped test tubes containing 3 mm glass beads and declumped once again as described above. The resulting supernatant was harvested and its turbidity adjusted using PBS to an optical density at 600 mm (OD 600 ) of $0.13 using a spectrophotometer (Biomate 3, Thermo Fisher Scientific, Waltham, MA, USA) to match a 0.5 McFarland turbidity standard. MGIT TM ParaTB medium tubes (Becton Dickinson) were inoculated with 0.1 mL of the MAP suspension (drug testing and growth control tubes) or a 100-fold dilution of the suspension (1:100 growth control). The organism was added to the culture medium 24 h prior to adding drugs in order to permit the bacilli to adjust to the growth conditions and prepare for log-phase growth. Tubes of MGIT TM ParaTB medium so inoculated were found to contain 1Â10 5 -5Â10 5 cfu/mL prior to adding drugs. Minor but consistent differences in growth rates were observed between strains as reflected in the time to detection (TTD) values in the MGIT system (discussed below).
Drugs
Azithromycin, clarithromycin, amikacin, ciprofloxacin, ethambutol, clofazimine and 6-mercaptopurine were purchased from Sigma-Aldrich (St Louis, MO, USA). Rifampicin and rifabutin were purchased from USP (Rockville, MD, USA). Stock solutions of drugs were prepared using the most appropriate solvent: water (amikacin and ethambutol); 0.1 N sodium hydroxide (ciprofloxacin); DMSO (6-mercaptopurine); methanol (rifampicin and rifabutin); ethanol (azithromycin and clarithromycin); or methanol acidified by trace amounts of glacial acetic acid (clofazimine). Drug stock solutions were filter sterilized, if required, and stored at 2808C for up to 2 months, except for 6-mercaptopurine, which was freshly made each time it was used. Prior to testing, each drug was freshly diluted in sterile deionized water.
In vitro drug interaction testing
The method described for mycobacteria was adapted for the BACTEC TM MGIT TM 960 system (Becton Dickinson). 26 Briefly, each drug in a combination (two-drug and three-drug combinations) was tested at their respective MICs and at up to five doubling dilutions (sub-MICs) for the strain being tested. Anticipating one doubling dilution difference from previously determined MICs, two more sets of combinations each containing one of the drugs at 2Â the MIC and doubling dilutions thereof were tested. MICs of each individual drug were re-determined in the same experiment in which drug combinations were tested. All drug dilutions as either individual drugs or combinations were added to the culture medium in a total volume of 0.1 mL.
Tubes were incubated in the MGIT TM 960 instrument and growth was recorded as a TTD value. The TTDs for the strains ranged from 2.5 to 4.4 days (average 3.56+0.69) in control tubes and from 7 to 12.7 days (average 9.87+1.86) in 1% control tubes. The MIC of individual drugs was defined as the lowest drug concentration required to suppress MAP growth resulting in a TTD greater than that of the 1% growth control. The MIC of a drug in a combination (MIC comb ) was defined as the lowest concentration of that drug in the mixture that resulted in a TTD greater than the 1% growth control.
The fractional inhibitory concentration (FIC) of each drug in a mixture was calculated as MIC comb /MIC. Drug interaction was determined based on the FIC index (FICI) for the specific drug combination, which is the sum of FICs.
For two-drug combinations, drug interactions were considered synergistic if the FICI was 0.5 and antagonistic if the FICI was .4.0; there was considered to be no interaction if the FICI was .0.5 and 4.0.
27
Results and discussion
6-Mercaptopurine -antibiotic combinations
It was recently shown that the immunosuppressive drugs azathioprine and its metabolite 6-mercaptopurine have anti-MAP activity. 23, 24 These drugs could potentially affect the activity of antimicrobials when used together for treatment of CD. We assessed drug interactions in vitro by determining the FICI values of two-drug (6-mercaptopurine plus antimicrobial) combinations containing 6-mercaptopurine and one of the eight antibiotics that showed in vitro anti-MAP activity in our previous study. 16 MICs of 6-mercaptopurine for the MAP isolates used in the present study ranged from 1 to 128 mg/L. We have previously observed that the MBCs of 6-mercaptopurine for all the nine strains were .128 mg/L, the highest concentration tested. Even for a strain having an MIC of 1 mg/L, there was only a 0.4 log 10 reduction in cfu at 64 mg/L and there was no concentration-dependent killing. These data suggest that the drug is bacteriostatic to MAP. Antimicrobial drugs either showed synergy or no interaction with 6-mercaptopurine, and none of the combinations was antagonistic for MAP growth inhibition in vitro (Table 1) . Azithromycin showed a synergistic interaction with 6-mercaptopurine for seven out of the nine MAP strains, while clarithromycin, rifampicin and rifabutin showed synergy with 6-mercaptopurine for four MAP strains each. Ethambutol was synergistic with 6-mercaptopurine for only two MAP strains. Anti-MAP activities of amikacin, ciprofloxacin and clofazimine were not affected by 6-mercaptopurine for any of the nine MAP isolates tested. Individual MICs and FICI values for all nine strains are shown in Table 2 . This is the first in vitro drug combination study on 6-mercaptopurine and antibiotics as anti-MAP agents and is relevant for the treatment of CD cases that are associated with MAP. In humans, azathioprine is rapidly converted into 6-mercaptopurine, which in turn is metabolized to TGNs-the active metabolites responsible for immunosuppression. 22 The low serum levels (,0.1 mg/L) and short half-lives (1 -3 h) of 6-mercaptopurine are attributed to its rapid conversion into TGNs. 28, 29 The concentrations of active metabolites and toxic metabolites of 6-mercaptopurine are known to vary among and within individuals due to the complexity of the metabolic pathways involved and genetic polymorphisms in the metabolizing enzymes. 30 TGN concentrations approaching 250 pmol/8Â10 8 red blood cells are reported to be associated with disease remission. 22 Currently it is not known how 6-mercaptopurine inhibits the growth of MAP or whether the bacterium actively converts 6-mercaptopurine into TGNs. In this scenario, even though the in vitro data presented here are not sufficient to predict the clinical efficacy of synergistic 6-mercaptopurine -antibiotic combinations on MAP, it is encouraging to find that these combinations can be synergistic or neutral in their effects, but not antagonistic.
Drug combinations containing clarithromycin
Two-drug combinations, containing clarithromycin and one of the four anti-MAP agents amikacin, rifampicin, ciprofloxacin or ethambutol (each belonging to different antimicrobial drug classes), were tested against nine MAP isolates. In addition, a three-drug combination containing clarithromycin, rifabutin and clofazimine, a common combination used in CD trials targeting MAP, was tested against three MAP strains. Clarithromycin when combined with rifampicin showed either synergism (four isolates) or no effect (five isolates) on inhibition of MAP growth in vitro (Table 3 ). The other three drugs, amikacin, ciprofloxacin and ethambutol, did not show any interaction with clarithromycin for any of the nine MAP isolates tested. The three MAP isolates tested with the three-drug combination, clarithromycin, clofazimine and rifabutin, did not show any drug interaction. Individual MIC and FICI values for all nine strains for two-drug combinations containing clarithromycin are shown in Table 4 .
Clarithromycin in our earlier in vitro study was highly active against MAP, with MICs ranging between 0.125 and 1.0 mg/L. 16 Similar observations have been made in the past by others. 15 The drug has also been tested as an anti-MAP agent in clinical trials against CD. 12, 14, 20 In the only prior report on the effect of drug combinations on in vitro growth of MAP, the combination of clarithromycin and ethambutol showed synergy for three of four MAP strains. 15 More drug interaction studies have been reported on M. avium isolates. Piersimoni et al. 31 demonstrated synergistic activity of clarithromycin with rifabutin, ethambutol and ciprofloxacin in 54%, 16% and 8% of 37 clinical M. avium isolates, respectively. In another study on M. avium clinical isolates, clarithromycin activity was enhanced by ethambutol and rifampicin in eight and three of nine strains tested, respectively. 32 The study demonstrates the utility of a rapid (8-10 days) screening method for study of anti-MAP drug interactions in a research setting prior to ex vivo and in vivo experiments. This in vitro study also demonstrates, for the first time, potential synergistic anti-MAP effects of 6-mercaptopurine -antibacterial drug and clarithromycin -rifampicin drug combinations.
